AbbVie Inc. (ABBV): Operating Income
$15.07B
Year ended 2025-12-31
$16.87B
Trailing 12 months to 2026-06-30
-5.9%
3-year compound annual growth
+5.8%
5-year compound annual growth
+7.2%
10-year compound annual growth
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $15.07B | +65.0% | 2026-02-20, From 2025-01-01 |
| 2024-12-31 | $9.14B | -28.4% | 2026-02-20, From 2024-01-01 |
| 2023-12-31 | $12.76B | -29.6% | 2026-02-20, From 2023-01-01 |
| 2022-12-31 | $18.12B | +1.1% | 2025-02-14, From 2022-01-01 |
| 2021-12-31 | $17.92B | +57.7% | 2024-02-20, From 2021-01-01 |
| 2020-12-31 | $11.36B | -12.5% | 2023-02-17, From 2020-01-01 |
| 2019-12-31 | $12.98B | +103.4% | 2022-02-18, From 2019-01-01 |
| 2018-12-31 | $6.38B | -33.1% | 2021-02-19, From 2018-01-01 |
| 2017-12-31 | $9.54B | +2.2% | 2020-02-21, From 2017-01-01 |
| 2016-12-31 | $9.34B | +23.9% | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | $7.54B | +121.0% | 2018-02-16, From 2015-01-01 |
| 2014-12-31 | $3.41B | -39.8% | 2017-02-17, From 2014-01-01 |
| 2013-12-31 | $5.66B | -2.6% | 2016-02-19, From 2013-01-01 |
| 2012-12-31 | $5.82B | +60.7% | 2015-02-20, From 2012-01-01 |
| 2011-12-31 | $3.62B | n/a | 2014-02-21, From 2011-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| AbbVie Inc. (ABBV) | 2025-12-31 | $15.07B | +65.0% |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.05B | +18.0% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $2.16B | n/m |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $3.58B | -10.3% |
| Viatris Inc (VTRS) | 2025-12-31 | -$2.66B | n/m |
| Vertex Pharmaceuticals Inc (VRTX) | 2025-12-31 | $4.17B | n/m |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $1.81B | +17.3% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $447.14M | n/m |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | -$430.24M | n/m |
Compare ABBV, ABT, TEVA, REGN side by side · Screen every company in Pharmaceutical Preparations ↗